LCZ696
Novartis heart failure drug available via EAMS
September 3, 2015Sales and Marketing Early Access to Medicines Scheme, Entresto, LCZ696, MHRA, Novartis, eams, heart failure, sacubitril/valsartan
Novartis has won the investigational heart failure treatment LCZ696 (sacubitril valsartan) will be available in the UK under the Early …
Novartis wins US nod for new heart drug
July 8, 2015Research and Development, Sales and Marketing Entestro, FDA, LCZ696, Novartis, ejection fraction, heart failure, reduced ejection fraction, sacubitril
The FDA has given the green light to Novartis’ new heart failure drug, six weeks ahead of the scheduled date …
Novartis heart drug steps closer to EAMS scheme
April 23, 2015Sales and Marketing LCZ696, MHRA, Medicines and Healthcare products Regulatory Agency, NICE, eams, pim, sacubitril/valsartan
Novartis’ investigational heart failure drug LCZ696 has been handed a Promising Innovative Medicine designation (PIM) after showing that it significantly …
FDA approves Eisai thyroid drug, fast-tracks Novartis heart pill
February 16, 2015Sales and Marketing Eisai, FDA, LCZ696, Lenvima, Novartis, heart, lenvatinib, thyroid
The FDA has approved Eisai’s thyroid cancer drug Lenvima and also granted Novartis heart pill LCZ696 a priority review. Lenvima …
Novartis heart drug sees stellar results
September 1, 2014Sales and Marketing Diovan, LCZ696, Novartis, failure, heart, valsartan
Novartis’ new heart pill has produced stellar results in helping patients with heart failure live longer, making it the first …
